Creating a Global Company

Key Financials Q3 & 9m FY22 SUN PHARMA Q3 FY22 Q3 FY21 CHANGE 9m FY22 9m FY21 (All Figures in Rs. Mn) CHANGE Gross Sales 98,142 88,088 11.4% 290,403 247,693 17.2% Gross Profit 71,736 64,754 10.8% 212,284 183,200 15.9% Gross Margin 73.1% 73.5% 73.1% 74.0% EBITDA 25,574 23,782 7.5% 78,900 62,371 26.5% EBITDA Margin 26.1% 27.0% 27.2% 25.2% Net Profit 20,588 18,524.8 11.1% 55,500 20,097 176.2% Net margin 21.0% 21.0% 19.1% 8.1% Net Profit (Adjusted) 20,588 18,524.8 11.1% 60,851 45,887 # 32.6% Net margin (Adjusted) 21.0% 21.0% 21.0% 18.5% R&D 5,471 5,595 -2.2% 16,761 15,928 5.2% R&D as % of Net Sales 5.6% 6.4% 5.8% 6.4% EPS (Diluted) INR 8.6 7.7 11.1% 23.1 8.4 176.2% EPS (Diluted) INR (Adjusted) 8.6 7.7 11.1% 25.4# # 19.1" 32.6% # 9m FY22 - Adjusted for Rs. 5.3 bn provision (related to (i) US MDL (Taro) = Rs. 4,425 mn (ii) write down of a manufacturing facility=Rs. 382 mn (iii) Dexasite impairment = Rs. 1,503 mn. Taro provisions are adjusted for minority interest) # 9m FY21 - Adjusted for Rs. 28 bn provision (related to US DOJ (Taro) = Rs. 36,333 mn.) & adjusted for Rs. 2.2 bn provision (related to deferred tax gain (Taro) = Rs. 2,883 mn.) Taro provisions are adjusted for minority interest. 50

View entire presentation